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A B S T R A C T
Since 2013, North America has experienced a sharp increase in unintentional fatal overdoses: fentanyl, and its
analogues, are believed to be primarily responsible. Currently, the most practical means for people who use
drugs (PWUD) to avoid or mitigate risk of fentanyl-related overdose is to use drugs in the presence of someone
who is in possession of, and experienced using, naloxone. Self-test strips which detect fentanyl, and some of its
analogues, have been developed for oﬀ-label use allowing PWUD to test their drugs prior to consumption. We
review the evidence on the oﬀ-label sensitivity and speciﬁcity of fentanyl test strips, and query whether the
accuracy of fentanyl test strips might be mediated according to situated practices of use. We draw attention to
the weak research evidence informing the use of fentanyl self-testing strips.
This journal has drawn attention to the urgent need for developing
harm reduction interventions in response to the harm producing eﬀects
of fentanyl in the heroin supply, which are linked to appreciable in-
creases in rates of opioid overdose in some settings (Ciccarone, 2017).
Fentanyl and its analogues (i.e. fentanyls) are linked to the signiﬁcant
increase in fatal opioid overdoses in North America since 2013 (United
Nations Oﬃce on Drugs and Crime, 2017b). Despite widespread media
attention, and repeated public health alerts, fatal overdoses continue to
rise (Seth, Scholl, Rudd, & Bacon, 2018; Special Advisory Committee on
the Epidemic of Opioid Overdoses, 2018). In 2016, 19,413 people died
from unintentional overdoses involving synthetic opioids other than
methadone in the United States, representing a two fold increase from
2015 (Seth et al., 2018). In Canada, there were 2,946 opioid-related
deaths in 2016. Preliminary data indicate that 2,923 people died of
opioid-related overdose between January and September 2017, with
72% of these involving fentanyl or fentanyl analogues (compared to
55% in 2016) (Special Advisory Committee on the Epidemic of Opioid
Overdoses, 2018). Fentanyl-related overdoses have also been docu-
mented throughout Europe, as well as in Asia, North Africa, and
Oceania (United Nations Oﬃce on Drugs and Crime, 2017a). Since
2014, six fentanyl variations have been identiﬁed in the UK drug
market, with a spate of overdoses attributed to fentanyl occurring in the
North East of England in 2017 (BBC, 2017; Bryant, 2017). The case for a
rapid harm reduction response is self-evident (Ciccarone, 2017). Calls
have been made for upscaling community-based overdose prevention
interventions, especially the peer distribution of naloxone, alongside
the development of drug checking and drug testing interventions de-
signed to detect the presence of fentanyl in the drug supply (Ciccarone,
2017; Fairbairn, Coﬃn, & Walley, 2017). In this commentary, we
consider the feasibility and acceptability of drug testing strips as a
means for users to self-minimise their overdose risk related to unin-
tentional fentanyl use. We endorse the need to act urgently, yet note
that self-testing interventions are not without risk or uncertainty.
Fentanyl and overdose risk
Fentanyl is estimated to be 50–100 times ‘stronger’ than morphine
(Centers for Disease Control and Prevention, 2018). Public health
messaging commonly references the relative potency by weight of
fentanyl compared to morphine despite the fact that opioid equia-
nalgesic conversion tables are both variable and inconsistent (Centers
for Disease Control and Prevention, 2018; Shaheen, Walsh, Lasheen,
Davis, & Lagman, 2009). Lethality, rather than potency, is a more re-
liable risk indicator; however, there is currently no standard or com-
parable measure of acute fentanyl lethality in humans. The median
lethal dose (LD50) for fentanyl in rats is 3.1 mg/kg, compared to
22.5 mg/kg for heroin, suggesting a seven-fold increase in toxicity –
though the relative lethality in rats may not equate to the relative
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lethality in humans (International Programme on Chemical Safety
(INCHEM), 2017; National Center for Biotechnology Information,
2017a). Despite the lack of certainty about the relative strength of
fentanyl, it is incontrovertible that fentanyl (and many of its analogues)
is lethal at much lower doses than other opioids, and is signiﬁcantly
more potent by weight when compared to heroin.
The increase in fatal overdoses since 2013 has been largely attrib-
uted to the use of heroin adulterated with non-pharmaceutical fentanyls
and, to a lesser extent, diverted pharmaceutical fentanyl (Daniulaityte
et al., 2017; Gladden, Martinez, & Seth, 2016; Massey et al., 2017; Seth
et al., 2018; United Nations Oﬃce on Drugs and Crime, 2017b). Illeg-
ally produced fentanyls provide a potent, low-cost and low-bulk syn-
thetic opioid – attractive as an addition to high-cost and/or low-purity
heroin. It is posited that restrictions in the heroin supply due to Taliban
control of opium production have contributed to the most recent inﬂux
of fentanyl-contaminated heroin into Europe (Mounteney, Giraudon,
Denissov, & Griﬃths, 2015). Nearly all of the fentanyl entering the
United States originates in either China or Mexico (United States Drug
Enforcement Administration, 2017). Most of the heroin in the US comes
from Mexico and is both inexpensive and of relatively high purity; thus,
the motivation for introducing fentanyls to the US heroin market is
unclear (United States Drug Enforcement Administration, 2016).
The contamination of illegal drugs, such as heroin, with fentanyl
makes it diﬃcult for even the most experienced drug user to anticipate
and mitigate the likelihood of overdose. Those with less experience,
who are often most vulnerable to overdose, are less likely to consume
drugs in the company of those who have experience of, and access to,
naloxone (Frank et al., 2015; Neira-Leon et al., 2011). Despite the ef-
fectiveness of naloxone in reversing opioid overdose (Clark, Wilder, &
Winstanley, 2014), US states and many Canadian provinces have been
slow to facilitate naloxone distribution and actively endorse its use
(Cressman et al., 2017; Human Rights Watch, 2017).
Fentanyl is often implicated as the cause of excess fatal overdoses;
however, fentanyl analogues are thought to be contributing (either
alone or in combination with fentanyl) to a signiﬁcant proportion of
these deaths (United Nations Oﬃce on Drugs and Crime, 2017b). Evi-
dence from a sero-survey of unintentional fatal overdoses in Ohio
showed the presence of multiple fentanyl analogues among fentanyl-
positive decedents including: acrylfentanyl, carfentanil, and fur-
anylfentanyl (Daniulaityte et al., 2017). In a recent report of fentanyl-
related deaths across 10 US states, fentanyl analogs were detected in
toxicology from 720 (14%) of 5,152 opioid overdose deaths including:
carfentanil (in 389 deaths, 7.6%), furanylfentanyl (in 182 deaths,
3.5%), and acetylfentanyl (in 147 deaths, 2.9%) (O'Donnell, Halpin,
Mattson, Goldberger, & Gladden, 2017). Fentanyl analogues are not
always included in toxicological tests, and are often diﬃcult to detect,
suggesting that toxicological surveys may underestimate their occur-
rence (O'Donnell et al., 2017).
In March 2017, the UN Commission on Narcotic Drugs, in an at-
tempt to curb illegal manufacturing, scheduled two fentanyl precursors
and a fentanyl analogue, bringing them within the ambit of the UN drug
treaty control framework (United Nations Oﬃce on Drugs and Crime,
2017a). There is little indication that supply-side controls will have an
impact on availability; rendering harm reduction initiatives, largely in
the form of risk reduction messaging, the primary means through which
people who use drugs (PWUD) can mitigate their risk. Risk reduction
advice includes not using drugs alone, taking a ‘test hit’ or smoking (of
brown heroin) a sample of drugs before injecting, and ensuring that
naloxone is available for bystander administration (Australian Injecting
& Illicit Drug Users League, 2013; Ciccarone, 2017; Release, 2017;
Toward the Heart, 2018). Health Canada actively encourages PWUD to
consume drugs at a supervised injection facility (Health Canada, 2017).
Supervised injection facilities have contributed to population-level re-
ductions in fatal overdose (Marshall, Milloy, Wood, Montaner, & Kerr,
2011), and oﬀer potential in reducing fentanyl-related overdose
(Ciccarone, 2017).
Recently, there have been calls for promoting point-of-use drug
testing as a means of detecting fentanyl to prevent unintentional fen-
tanyl use and related overdose risk (Harris, 2017; Stewart, 2017;
Vancouver Coastal Health, 2017a, 2017b). Fentanyl self-test strips (i.e.
lateral ﬂow immunochromatographic assays), when dipped into a so-
lution containing dissolved drugs, can indicate the presence of fentanyl.
As the test strips have only recently become available we are faced with
a considerable amount of uncertainty regarding the evidence in support
of their use, and their potential to reduce fentanyl overdose risk. Spe-
ciﬁcally, what do we know of their sensitivity, speciﬁcity, availability,
and feasibility, including harm-reducing relative to harm-producing
potential? Crucially, do we know enough to act, to upscale the pro-
motion and distribution of self-testing interventions among opioid
users? We emphasise the critical importance of integrating self-testing
interventions inside a broader package of harm reduction intervention
and support.
Testing for fentanyl and fentanyl analogues
In Canada, fentanyl test strips are licensed as an in vitro diagnostic
medical device for urinalysis and, as such, may only be sold directly to
laboratories or health care professionals. However, the same test strips
are also sold as a forensic test and can thus be used, oﬀ-label, to test
drugs dissolved in solution. Forensic tests do not require licensing and
may be lawfully sold to anyone. On 7 July, 2016, Vancouver Coastal
Health began an evaluation of the oﬀ-label application of the test strips
at the Insite Supervised Injection Site (Stewart, 2017). The evaluation
found that 86% of all drug samples (including heroin, cocaine, etc.), and
90% of the ‘heroin’ samples, tested positive for fentanyl (Vancouver
Coastal Health, 2017a, 2017b). This may be an overestimate, however,
as most of the checks (62%) were performed post-consumption, and it is
likely that PWUD may be more inclined to test drugs about which they
have become suspicious (Lysyshyn, Dohoo, Forsting, Kerr, & McNeil,
2017; The Vancouver Sun, 2017). It also raises concerns about the
potential excessive sensitivity of urinalysis tests when used oﬀ-label
with drug solution. Currently, “[the test strips] could possibly pick up
levels of fentanyl that are well below psychoactive doses from the air or
contamination of powder during handling in the supply chain”
(Exchange Supplies, 2018). A high frequency of positive test results,
particularly when received post-consumption with no associated ill-ef-
fects, can lead to complacency, limit risk-reduction measures, and may
impact testing acceptability among users.
In November 2017, Judy Darcy, Minister of Mental Health &
Addictions, announced that the Ministry is expanding the use of fen-
tanyl test strips to all supervised injection sites in British Columbia
(CBC News, 2017). Formalised initiatives to promote fentanyl test strips
appear to be limited to supervised facilities. Caution about the sensi-
tivity and speciﬁcity of oﬀ-label use is reﬂected in Health Canada’s
recent warning that: “[s]ome individuals and organizations are using
test strips to detect fentanyl by dissolving a small amount of drugs in a
solution. These test strips have not been designed for direct use by
consumers in this way, which could lead to false negative results”
(Health Canada, 2017). As noted above, false positives – or positive
results at below psychoactive dosage levels, may also have detrimental
impact.
Clear evidence on the sensitivity and speciﬁcity of fentanyl test
strips when used oﬀ-label is crucial for informing associated harm re-
duction strategies. BNTX Inc, the manufacturer of the test strips used in
Vancouver, report that the strips are> 98% accurate at detecting fen-
tanyl in urine (BTNX Inc, 2017). The potential for low speciﬁcity re-
garding psychoactive dose and associated toxicity is not addressed. The
test strips are apparently able to detect, “many other fentanyl analogues
such as carfentanil, acetylfentanyl, butyrylfentanyl, 3-methylfentanyl,
ocfentanil, [and] sufentanil” (BTNX Inc, 2017). The recent Fentanyl
Overdose Reduction Checking Analysis Study (FORECAST) compared
the BTNX fentanyl testing strips, to a Raman spectroscopy (i.e. TruNarc)
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machine, and a Fourier-transform infrared spectroscopy (i.e. Bruker
Alpha) machine (Johns Hopkins Bloomberg School of Public Health,
2018). The study set out to determine the detection limit, sensitivity,
and speciﬁcity of the three technologies. The preliminary data from the
study indicate that the self-test strips, when used for oﬀ-label testing,
and compared to the other two technologies, had the lowest detection
limit (0.13mg/ml) and the highest sensitivity (96% and 100% for the
respective test sites) and speciﬁcity (90% and 98%) for fentanyl. The
test strips were also successful in identifying fentanyl analogues (acet-
ylfentanyl, furanylfentanyl, and furanylfentanyl in combination with
heroin) (Johns Hopkins Bloomberg School of Public Health, 2018).
Additional evaluation of these strips conducted by DanceSafe and the
University of California San Francisco found that they performed better
than other test strips on the market and detected most fentanyl analo-
gues, including carfentanil at “miniscule concentrations” (DanceSafe,
2017). However, a preliminary study of the eﬃcacy of the test strips
found that seven out of 70 drug samples tested returned erroneous or
invalid results leading Health Canada to limit its endorsement of drug-
checking services to approved supervised consumption sites only,
“where individuals have access to personnel who are trained in over-
dose response” (Health Canada, 2017; Ireland, 2017).
Health Canada’s response may appear to be overly cautious, given
the 90% accuracy of the test strips and the critical need to respond to
high rates of fatal overdose. The frequency of drug use among PWUD
with a high tolerance (who may inject up to six times a day) may,
however, render this relatively high accuracy problematic. It is unclear
also whether sensitivity and speciﬁcity might diﬀer according to the
situated practices of fentanyl test strip use. Drug preparation practices
diﬀer geographically – determined, in part, by the type of heroin
available (Ciccarone & Harris, 2015). It is unknown whether the use of
acidiﬁers in drug preparation will aﬀect test accuracy. The solution into
which drugs are dissolved has been shown to reduce the accuracy of
reagent tests (Quest & Horsley, 2007). This is important in the Eur-
opean context, where brown (base) heroin requires citric acid, vitamin
C, or another acidiﬁer to prepare it for injection. Situated practices of
street injection, where drug preparation is often – of necessity – more
hurried and constrained, may also impact test strip acceptability and
use (Rhodes et al., 2007). The two to ﬁve minutes required for the test
result to register might, for example, be an impossibility in a street
injecting situation or for those experiencing acute withdrawals.
Despite these uncertainties, and a lack of peer-reviewed evidence to
date about the eﬃcacy and eﬀectiveness of self-testing in fentanyl
overdose prevention, test strips are becoming increasingly available for
home use. The test strips are distributed by various harm reduction
agencies, and are available to order online (Bebinger, 2017; DanceSafe,
2017; Exchange Supplies, 2018; O'Brien, 2017). This can be seen as
pragmatic – and needed – response to the exigencies of an overdose
epidemic, but the vacuum (of situated evidence, of comprehensive and
supportive harm reduction interventions) in which this response is oc-
curring requires critical reﬂection.
Self-testing of club drugs using reagent kits
In the absence of suﬃcient research speciﬁc to fentanyl testing, we
can consider the potential harm reducing impact of interventions for
testing club drugs. Self-testing for MDMA, for example, involves placing
a tablet into a reactive solution which changes colour indicating the
presence of any number of substances. Evidence from their evaluation
show that sensitivity and speciﬁcity is reduced with considerable po-
tential to misinterpret results when used by people unfamiliar with the
reagent tests (Murray et al., 2003). Given these uncertainties, experts
do not recommend their use as a harm reduction tool, recommending
instead the use of more rigorous testing methods (e.g. infrared spec-
troscopy) that are carried out by a trained technician and which provide
accurate results, as well as a precise breakdown of a pill’s constituents
(European Monitoring Centre for Drugs and Drug Addiction, 2001;
Murray et al., 2003). Similarly, a study of a reagent test for detecting
potentially incapacitating concentrations of y-hydroxybutyric acid
(GHB) and ketamine in drinks determined that the accuracy of the test
in a laboratory setting was 100%, but reduced to 65% (sensitivity 50%,
speciﬁcity 91.6%) when applied by users (Quest & Horsley, 2007).
Even when self-test kits are eﬀective and accurately interpreted
with respect to the presence of MDMA, they may not indicate the
presence of other substances, which may be individually harmful or
which might result in cumulative toxicity (Schneider, Galettis,
Williams, Lucas, & Martin, 2016). Additionally, the user is often unable
to anticipate the eﬀect of the drug until after it is consumed, regardless
of what is indicated by the test (i.e. conﬁrming that presence of a drug
does not protect against idiosyncratic adverse eﬀects that are re-
sponsible for many MDMA-associated fatalities). Factors inherent to the
individual (e.g. tolerance, metabolism) may contribute to individual
vulnerability and may not be taken into account, particularly when the
pill itself is presumed to be the locus of risk (Schneider et al., 2016).
Finally, MDMA self-test kits give no indication of the strength of a pill
(Winstock, Wolﬀ, & Ramsey, 2001).
Though self-testing of club drugs suggests the potential for both
inaccurate and incomplete results, there are additional important con-
cerns about the proper use and interpretation of these self-tests when
administered by a lay user. Studies of self-testing of club drugs has
demonstrated that self-testing is of limited value if not delivered within
a package of harm reduction services including the provision of accu-
rate information for reducing the risk of adverse outcomes, and for
intervention in the case of overdose (European Monitoring Centre for
Drugs and Drug Addiction, 2001).
What do we need to know about fentanyl self-testing?
Given the severity of the opioid overdose epidemic in North
America and the emergence of fentanyl-adulterated heroin in multiple
countries, there is an urgent need to evaluate drug self-testing in the
context of situated opioid use (Socias & Wood, 2017). Fentanyl test
strips are currently being distributed for self-testing outside of su-
pervised injection facilities, despite a limited evidence-base – including
any published ethical deliberation – informing their design and im-
plementation. In order to understand the potential eﬀect of fentanyl
self-testing, it is critical to appreciate how the test strips will be used
and interpreted in the lived contexts of everyday opioid use, and
whether they will be perceived acceptable among potential users of the
technology. There is a need also, to consider the potential of any un-
intended consequences that might increase risk or harm – beyond the
obvious risk of false negatives – and how these might be balanced
against the alternatives, of which, currently, there are few.
Use
Fentanyl test strips require that drugs are diluted in water before the
test strip can be applied. Only one of the test kits currently available
includes a ‘test buﬀer bottle’ for diluting and testing a drug sample
(Exchange Supplies, 2018). The majority of the available test kits in-
clude a test strip only; in this case, it is likely that drug preparation
would occur, followed by application of the test strip to the drug so-
lution or to the cooker residue after drug consumption. With the drugs
already in solution, the user’s obvious options to mitigate harm involve
incremental dosing, swallowing, or simply disposing of the drugs.
Incremental dosing or taking a ‘test hit’ or ‘taster shot’ prior to in-
jecting the remaining dose is likely to be a common response – a risk
reduction measure often employed when the user suspects that the drug
has been adulterated, or to reduce the likelihood of overdose after a
period of abstinence (Preston & Derricott, 2017). There are no data to
evidence the eﬀectiveness of incremental dosing for fentanyl and its
analogues; the enhanced potency of many fentanyls (particularly of
carfentanil) may render this approach ineﬀective in reducing the risk of
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overdose. The dissolution proﬁle of fentanyl, and its analogues, may
also pose problems when incremental dosing (National Center for
Biotechnology Information, 2017a, 2017b). Brown heroin, which is
widely available throughout Europe, may dissolve at a slower rate in an
acid solution than fentanyl, initially leaving heroin residual in the
cooker, and a higher relative concentration of fentanyl in the drug so-
lution. Though this is not a risk when dissolving white heroin (which is
the predominant form of heroin in North America), fentanyl and its
analogues may still be unevenly distributed between samples. In-
digenous harm reduction strategies may develop in response to such
situations – such as intranasal use (i.e. using a nasal spray device).
Eﬀect
Fentanyl is known to change the nature of the drug use experience
and there is evidence that this may be desired among some people who
use drugs (Ciccarone, Ondocsin, & Mars, 2017; Harris, 2017; Johns
Hopkins Bloomberg School of Public Health, 2018). In such circum-
stances a positive test result may be sought after, or at least not act as a
disincentive to use – particularly among those experiencing opioid
withdrawal. It is crucial, therefore, that community acceptable strate-
gies to mitigate associated risks of fentanyl use are evidenced and
disseminated. Learning from those who purposefully and safely use il-
licit fentanyl − alongside study of situated responses to positive test
results will be invaluable. During the 2010/2011 heroin shortage in the
UK, despite widespread knowledge of adulteration (largely, in this case,
with benzodiazepines), and associated negative experiences (such as
blackouts, memory loss), people continued to use heroin feeling that the
risk was unavoidable given the immediate need to alleviate withdrawal.
Indigenous harm reduction strategies, such as testing for adulterants by
viewing how heroin ‘ran’ when heated on a foil, were not always suc-
cessful (Harris, Forseth, & Rhodes, 2015).
One limitation of the test strips is that they do not give any in-
dication of how much fentanyl – or fentanyl analogues – is present. As
some fentanyl analogues (e.g. carfentanil) are toxic in signiﬁcantly
lower does than fentanyl, it seems unlikely that the test can be cali-
brated to reduce sensitivity to fentanyl without increasing the risk of
false negatives in drugs that contain only carfentanil for example. Part
of the potential of the test strips as a harm reduction tool stems from
their cross-reactivity with many fentanyl analogues. Given that many
analogues are lethal in lower doses than fentanyl, and given that they
have been found to be present in the absence of fentanyl (O'Donnell
et al., 2017), reducing the sensitivity of the test strips to fentanyl –
thereby increasing the speciﬁcity – may reduce the overall utility of the
test. Contamination of injection equipment may also result in a positive
test result and, though many people who use drugs do not share or re-
use syringes, sharing and/or reusing spoons is not uncommon
(McGowan, Harris, & Rhodes, 2013). It is unclear if a test which rou-
tinely indicates a non-fatal concentration of fentanyl, or indicates the
presence of a less potent analogue, will promote complacency as people
witness or experience non-fatal/pleasurable use of drugs for which a
positive test result has been indicated.
Acceptability
There is currently limited evidence on the acceptability of the test
strips among people who use drugs. The Insite evaluation reported that
of the average 600 daily supervised injection site users, an average of
only 4.7 checks were performed per day (Lysyshyn et al., 2017). Re-
ports that “clients who checked prior to consumption and got a positive
result were 10 times more likely to reduce their dose, and clients who
reduced their dose were 25% less likely to overdose” (Vancouver
Coastal Health, 2017a, 2017b) refer therefore, to a small minority of
clients who chose to test their drugs. The FORECAST study reported
that the majority of their 256 research participants (73%) expressed
moderate to high interest in knowing if fentanyl is present in their
drugs, with 70% indicating that knowing their drugs contained fentanyl
would inspire them to modify their behaviour; however, the study did
not report speciﬁcally on the acceptability of fentanyl test strips among
PWUD (Johns Hopkins Bloomberg School of Public Health, 2018).
In America, recent increases in drug use have largely occurred in
demographics with historically low heroin use (e.g. women, the pri-
vately insured, and people with higher incomes) (Centers for Disease
Control and Prevention, 2015). Shifts in the proﬁle of American drug
users are thought to reﬂect transitions from prescription opioid use to
illegal opioid use (Compton, Jones, & Baldwin, 2016). This has rami-
ﬁcations for engagement with harm reduction services, as service access
is generally lower among women and those of higher socio-economic
status (Harris et al., 2015). Access to harm reduction services is likely to
be lower among these demographics, and among occasional users, due
to limited knowledge about available services or a hesitancy to engage
with services perceived to cater to the stigmatised, erroneously arche-
typal, ‘drug user’. Drug-using populations are becoming more diverse
geographically, with suburban users less likely to have access to harm
reduction services than those in urban catchment areas (Jozaghi &
Marsh, 2017). Ultimately, a considerable proportion of those at risk of
fentanyl-related overdose are people who are less likely to engage in
harm reduction interventions. It is unclear if test strips – even if they are
eﬀective – would reach those who are most at risk of obtaining fen-
tanyl-adulterated drugs. If they do reach those at risk, then their use by
those who are most likely to use drugs in a manner that is uninformed
by complimentary harm reduction recommendations (e.g. not using
drugs alone, or without naloxone) is problematic.
Do we know enough?
We draw attention to the weak research evidence informing the use
of fentanyl self-testing strips. Drug use and harm reducing intervention
eﬀects are subject to multiple situated contingencies (Rhodes, 2009).
How the eﬀect of an intervention of harm reducing potential is made
manifest is contingent upon its local meanings and implementations
(Rhodes, Closson, Paparini, Guise, & Strathdee, 2016). In considering
calls to upscale the promotion of fentanyl test strips to reduce overdose
risk, we emphasise the critical, urgent, and pragmatic potential of
qualitative and ethnographic research as a key dimension of im-
plementation science (Messac, Ciccarone, Draine, & Bourgois, 2013).
We point to a track record in the application of rapid situation assess-
ment methods in the ﬁeld of drug injection and harm reduction to hit
home the feasibility potential of developing rapid responses in im-
plementation science (Rhodes, Stimson, Fitch, Ball, & Renton, 1999).
We thus call for qualitative work, delivered within a rapid assessment
framework, to investigate the use, feasibility and acceptability potential
of fentanyl self-testing interventions, including alongside alternatives,
such as supervised-testing interventions and other overdose prevention
initiatives (including the peer distribution of naloxone). Importantly,
we draw attention to the need to investigate the unexpected and un-
intended eﬀects of self-testing interventions, including any risk poten-
tial. We note the importance of such qualitative research combining
with data about the pharmacokinetics and pharmacodynamics of fen-
tanyl and its common analogues to inform the harm reduction advice
oﬀered alongside the distribution of test strips. In addition, further in
vitro and oﬀ-label laboratory testing of the test strips is crucial to de-
termining their accuracy and the range of detectable analogues.
Research is needed in order to capture and evidence situated in-
digenous responses to emergent drug harm risks, particularly when
aligned with the use of new technologies such as self-testing. Now well-
evidenced public health responses to drug harms, such as needle and
syringe programs (NSP), stem from early community-led action to
combat the rise of HIV among PWID. Widespread ‘underground’ needle
and syringe distribution by activists in North American cities in the late
1970s and early 1980s provide an example of initiatives which arose in
the absence of controlled intervention studies, also in a context of
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prohibitions against the use of government funds for NSP evaluation
and/or promotion (Friedman et al., 2007). This context provides an
opportunity for implementation science to work alongside communities
to evidence and test the eﬃcacy of emergent fentanyl risk reduction
initiatives.
It is critical to act to reduce the overdose risks related to fentanyls. A
cautious approach is one which develops commensurate with the re-
lative knowns and unknowns of research and other evidence concerning
the eﬀect potential of harm-reducing interventions. An approach which
involves the distribution of test strips (with clear guidance on the in-
terpretation of results) alongside low threshold access to naloxone, and
integrated inside broader harm reduction responses, may serve to re-
duce the immediate risks of fatal overdose. Fentanyl and its analogues
are incredibly fast-acting requiring naloxone be administered im-
mediately; therefore, updated information on the use of naloxone to
reverse fentanyl overdose should also be provided alongside test strips.
Further, discouraging indigenous harm reduction methods that are
unlikely to reduce the risk of fentanyl overdose (e.g. determining the
presence of fentanyl by visually examining drugs), and encouraging the
use of drugs only when in the company of someone equipped with
naloxone, may mitigate the risk of false negatives and/or complacency.
Such risk reduction practices at once oﬀer opportunities for embedding
rapid situation assessment as part of intervention responses so as to
reﬂect immediately on how they work and whether they might be up-
scaled elsewhere.
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